Compare VREX & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VREX | AGMB |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 580.6M | 677.9M |
| IPO Year | 2016 | N/A |
| Metric | VREX | AGMB |
|---|---|---|
| Price | $11.97 | $11.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | $16.67 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 202.1K | 190.1K |
| Earning Date | 05-07-2026 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $811,000,000.00 | N/A |
| Revenue This Year | $5.35 | N/A |
| Revenue Next Year | $3.88 | $33.33 |
| P/E Ratio | $232.40 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.76 | $9.00 |
| 52 Week High | $14.57 | $17.45 |
| Indicator | VREX | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 61.43 | 49.08 |
| Support Level | $11.43 | $9.71 |
| Resistance Level | $12.61 | $12.06 |
| Average True Range (ATR) | 0.35 | 1.26 |
| MACD | 0.22 | 0.21 |
| Stochastic Oscillator | 89.06 | 86.27 |
Varex Imaging Corp Designs, manufactures, sells, and services X-ray imaging components, including X-ray tubes, detectors, ionization chambers, high-voltage connectors, software, collimators, generators, exposure control devices, and heat exchangers.. The company operates through two segments: Medical, the key revenue driver, providing X-ray imaging components and accessories for healthcare applications, and Industrial, which provides Linatron X-ray accelerators, X-ray tubes, flat panel detectors, high-voltage connectors, and coolers for non-medical use. Geographically, it generates the majority of its revenue from Europe, the Middle East, and Africa (EMEA), with the rest coming from the Americas and Asia Pacific.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.